With passion for patients and science, we are developing therapies for indications in the field of viral infectious diseases and autoreactive immune disorders.
Marinomed has the vision to transform the lives of people suffering from diseases with limited or no treatment options in two key therapeutic areas: virology and immunology. Driven by curiosity, patented technologies, and a deep understanding of the underlying science, we uncover unconventional paths no one has gone before.
Marinomed develops medicinal products and medical devices to help patients combat viral infectious diseases and autoreactive immune disorders.
Investors & ESG
Marinomed is listed on the prime market segment of the Vienna stock exchange since February 2019.
- Q1-Q3 2023 with stable revenues of € 7.2 million (Q1-Q3 2022: € 7.1 million)
- Marinosolv: progress in business…
- Marinomed and Nice & Green agree to resume flexible Convertible Notes Funding
Program with reduced tranches